HYOLIM KANG

Mathematical modeller in infectious diseases with specialisation in vaccine impact modelling for chikungunya; skilled in R and Stan; experienced in generating evidence to support vaccine policy decisions in collaboration with stakeholders.

• 1. Kang H, Auzenbergs M, Clapham H, Maure C, Kim JH, Salje H, Taylor CG, Lim A, Clark A, Edmunds WJ, Sahastrabuddhe S, Brady OJ, Abbas K. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study. Lancet Infect Dis. 2024 May;24(5):488-503. https://doi.org/10.1016/s1473-3099(23)00810-1
• 2. Kang H, Lim A, Auzenbergs M, Clark AD, Colón-González FJ, Salje H, Clapham HE, Carrera JP, Kim JH, Malarski M, Vergès SL, Cucunuba Z, Silva TC, Edmunds WJ, Sahastrabuddhe S, Brady O, Abbas K. Global, regional, and national Chikungunya burden and mapping force of infection: a spatial modelling study. 2024. SSRN (preprint). http://dx.doi.org/10.2139/ssrn.5048710 (Accepted in BMJ Global Health, in press)
• 3. Kang H, Lim A, Clark AD, Colón-González FJ, Clapham HE, Carrera JP, Kim JH, Auzenbergs M, Preethi L, Vergès SL, Sim SY, Han SM, Silva TC, Endy T, Cucunuba Z, Edmunds WJ, Sahastrabuddhe S, Brady O, Abbas K. Modelling age-specific chikungunya outbreak response immunisation strategies in Brazil: Broader implications for vaccine use case scenarios. SSRN. 2025. https://doi.org/10.2139/ssrn.5386779 (Under review in eClinicalMedicine)
• 4. Maure C, Khazhidinov N, Kang H, Auzenbergs M, Moyerson P, Abbas K, Santos GML, Medina LMH, Wartel TA, Kim JH, Clemens J, Sahastrabuddhe S. Chikungunya vaccine development, challenges, and pathway toward public health impact. Vaccine. 2024;42(26):126483. https://doi.org/10.1016/j.vaccine.2024.126483 (Corresponding author)
• 5. Auzenbergs M, Maure C, Kang H, Clark A, Brady O, Sahastrabuddhe S, Abbas K. Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis. PLoS Negl Trop Dis. 2024;18(4):e0012075. https://doi.org/10.1371/journal.pntd.0012075
• 6. Lim, A., Shearer, F.M., Sewalk, K., Pigott, D.M., Clarke, J., Ghouse, A., Judge, C., Kang, H., Messina, J.P., Kraemer, M.U. and Gaythorpe, K.A., 2025. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever. Nature Communications, 16(1), p.3418. https://doi.org/10.1038/s41467-025-58609-5
• 7. Shankar M, Hartner AM, Arnold CRK, Gayawan E, Kang H, Kim JH, Gilani GN, Cori A, Fu H, Jit M, Muloiwa R, Portnoy A, Trotter C, Gaythorpe KAM. How mathematical modelling can inform outbreak response vaccination. BMC Infect Dis. 2024 Dec 1;24(1):1371. https://doi.org/10.1186/s12879-024-10243-0
• 8. Kim, S., Kang, H., Skrip, L., Sahastrabuddhe, S., Islam, A., Jung, S.M., Vesga, J.F., Endo, A., Edmunds, W.J. and Abbas, K., 2025. Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response. Expert review of vaccines, 24(1), pp.183-193. https://doi.org/10.1080/14760584.2025.2476523